Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.42 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622014 | 1.00 | CHEK2 (0.49) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1622668 | 0.92 | CHEK2 (0.47) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1622674 | 0.92 | CHEK2 (0.47) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1622826 | 0.91 | CHEK2 (0.49) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1622822 | 0.91 | CHEK2 (0.49) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1623379 | 0.89 | CHEK2 (0.47) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL1623386 | 0.89 | CHEK2 (0.47) | CHEK2CCNE1CDK2KMT2AMEN1 | |
| SCHEMBL183924 | 0.89 | CHEK2 (0.56) | CHEK2KMT2AMEN1SMAD3 | |
| SCHEMBL1624858 | 0.89 | CHEK2 (0.56) | CHEK2KMT2AMEN1SMAD3 | |
| SCHEMBL183925 | 0.89 | CHEK2 (0.56) | CHEK2KMT2AMEN1SMAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885CCNE1 4812/4885CDK2 2974/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885CCNE1 4812/4885CDK2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.